Skip to main content

VT

ETF

Performance overview

VT Price
Price Chart

Forward-looking statistics

Beta
1.00
Risk
13.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Fund Profile

An ETF that provides investors with exposure to a broad range of global equities.

Fund info

An ETF that provides investors with exposure to a broad range of global equities.

Investing methodPassively Managed
DiversifiedYes
Expense ratio0.06%
Asset classEquities

Company info

Sector
Industry
Website
AUM$30.0B

Security info

ExchangeNyse American
Type of shareN/A
Earnings per share (EPS)
Dividend per share$1.54
Revenue per share
Avg trading volume (30 day)$292M
Avg trading volume (10 day)$330M
Put-call ratioN/A

Macro factor sensitivity

Growth+0.6
Credit+2.7
Liquidity-0.1
Inflation-1.7
Commodities-0.0
Interest Rates-1.2

Upcoming events

Next earnings day
Next dividend day
Ex. dividend dayMarch 21, 2025

News

Will Evertec (EVTC) Beat Estimates Again in Its Next Earnings Report?

Evertec (EVTC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research (July 21, 2025)
Revvity (RVTY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Revvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research (July 21, 2025)
VTRS Down on Late-Stage Study Failure of Eye Disease Drug

VTRS slides after phase III trial failure for blepharitis drug MR-139, adding pressure to an already struggling stock.

Zacks Investment Research (July 21, 2025)
Should Vanguard Value ETF (VTV) Be on Your Investing Radar?

Designed to provide broad exposure to the Large Cap Value segment of the US equity market, the Vanguard Value ETF (VTV) is a passively managed exchange traded fund launched on 01/26/2004.

Zacks Investment Research (July 21, 2025)
Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review

As the pharmaceutical industry increasingly focuses on developing targeted treatments for niche conditions, Viatris Inc. VTRS on Friday announced topline data from a Phase 3 study evaluating the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis.

Benzinga (July 18, 2025)
Ventas (VTR) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Ventas (VTR) have what it takes?

Zacks Investment Research (July 17, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free